Yanhong Feng from 3305 Arcola Rd, Collegeville, PA 19426, age 59, Phone: (610)5398592

Resumes

Yanhong Feng

view source

Us Patents

Quinoxaline Derivatives As Pi3 Kinase Inhibitors
view source
US Patent:

7592342, Sep 22, 2009
Filed:

May 8, 2008
Appl. No.:

12/117127
Inventors:

Yanhong Feng - Collegeville PA, US
Cynthia A. Parrish - Collegeville PA, US
Martha A Sarpong - Collegeville PA, US
Domingos J Silva - Collegeville CA, US
Assignee:

SmithKline Beecham Corporation - Philadelphia PA
International Classification:

A61K 31/498
US Classification:

514249, 544353
Abstract:

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.

Chemical Compounds
view source
US Patent:

20050004142, Jan 6, 2005
Filed:

Sep 10, 2002
Appl. No.:

10/489052
Inventors:

Jerry Adams - King of Prussia PA, US
Deborah Bryan - King of Prussia PA, US
Yanhong Feng - Collegeville PA, US
Shinichiro Matsunaga - Tsukuba-shi, JP
Yutaka Maeda - Tsukuba-shi, JP
Yasushi Miyazaki - Tsukuba-shi, JP
Masato Nakano - Tsukuba-shi, JP
Jean-Philippe Rocher - Vetraz-Mothoux, FR
Hideyuki Sato - Tsukuba-shi, JP
Marcus Semones - Collegeville PA, US
Domingos Silva - Collegeville PA, US
Jun Tang - Tsukuba-shi, JP
International Classification:

A61K031/519
C07D491/02
US Classification:

514260100, 544279000
Abstract:

Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

4-Amino-2,3-Disubstituted Thieno [2,3,D]Pyrimidines And Pharmaceutical Compositions Thereof
view source
US Patent:

20080287466, Nov 20, 2008
Filed:

Jul 9, 2008
Appl. No.:

12/169800
Inventors:

Jerry Leroy Adams - King of Prussia PA, US
Deborah Lynne Bryan - King of Prussia PA, US
Yanhong Feng - Collegeville PA, US
Shinichiro Matsunaga - Tsukuba-shi, JP
Yutaka Maeda - Tsukuba-shi, JP
Yasushi Miyazaki - Tsukuba-shi, JP
Masato Nakano - Tsukuba-shi, JP
Jean-Philippe Rocher - Vetraz-Mothoux, FR
Hideyuki Sato - Tsukuba-shi, JP
Marcus Semones - Collegeville PA, US
Domingos J. Silva - Collegeville PA, US
Jun Tang - Tsukuba-shi, JP
International Classification:

A61K 31/519
C07D 491/04
A61P 43/00
US Classification:

5142601, 544278
Abstract:

Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Quinoxaline Derivatives As Pi3 Kinase Inhibitors
view source
US Patent:

20100234386, Sep 16, 2010
Filed:

May 8, 2008
Appl. No.:

12/599544
Inventors:

Amita Chaudhari - Collegeville PA, US
Dashyant Dhanak - Collegeville PA, US
Carla Ann Donatelli - Collegeville PA, US
Thomas H. Faitg - Collegeville PA, US
Yanhong Feng - Collegeville PA, US
Steven David Knight - Collegeville PA, US
Cynthia A. Parrish - Collegeville PA, US
Jeffrey M. Ralph - Collegeville PA, US
Martha A. Sarpong - Collegeville PA, US
Domingos J. Silva - Collegeville PA, US
International Classification:

A61K 31/498
C07D 401/02
A61P 29/00
A61P 9/00
A61P 25/00
A61P 11/06
A61P 13/12
A61P 35/00
A61P 15/00
US Classification:

514249, 544353
Abstract:

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.

Chemical Compounds
view source
US Patent:

20110275611, Nov 10, 2011
Filed:

Nov 18, 2009
Appl. No.:

13/130368
Inventors:

Jeffrey Michael Axten - Collegeville PA, US
Yanhong Feng - Collegeville PA, US
Seth W. Grant - Collegeville PA, US
Jesus Raul Medina - Collegeville PA, US
William H. Miller - Collegeville PA, US
Stuart P. Romeril - Collegeville PA, US
International Classification:

A61K 31/506
C07D 417/14
C07D 413/14
C07D 401/14
A61K 31/541
A61K 31/5377
C07D 403/14
A61K 31/55
C07D 471/04
A61P 35/00
A61P 35/02
A61P 3/10
A61P 37/06
A61P 17/06
A61P 1/00
C07D 403/10
US Classification:

51421021, 544324, 544321, 544 62, 544122, 514275, 514272, 5142282, 5142345, 544331, 540599, 51421706, 5142342
Abstract:

The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R-Rare defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention